Table 5 Correlation between PIK3CA mutation status and response to neoadjuvant FAC/FEC or TFAC/TFEC chemotherapies
From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
FAC/FECa chemotherapy | TFAC/TFECa chemotherapy | ||||||
|---|---|---|---|---|---|---|---|
PIK3CA wild-type (n = 51) | PIK3CA mutation (n = 12) | P valueb | PIK3CA wild-type (n = 66) | PIK3CA mutation (n = 11) | P valueb | ||
Pathological complete response (pCR) versus residual disease (RD) | RD | 48 (94%) | 11 (92%) | 1.000 | 47 (73%) | 7 (70%) | 1.000 |
pCR | 3 (6%) | 1 (8%) | 17 (27%) | 3 (30%) | |||
Unknown | - | - | - | 2 | 1 | - | |
Residual cancer burden | 0 | 6 (17.6%) | 1 (16.7%) | 0.334 (0.474c) | 14 (24.6%) | 3 (33.3%) | 0.438 (0.613c) |
I | 2 (5.9%) | 0 (0%) | 5 (8.8%) | 0 (0%) | |||
II | 16 (47.1%) | 5 (83.3%) | 21 (36.8%) | 5 (55.6%) | |||
III | 10 (29.4%) | 0 (0%) | 17 (29.8%) | 1 (11.1%) | |||
Unknown | 17 | 6 | - | 9 | 2 | - | |